Edesa Biotech raises base pay for CEO, president and CFO
The board approved salary increases for Pardeep Nijhawan, Michael Brooks and Peter Weiler, retroactive to July 1, 2026.
Edesa Biotech, Inc. disclosed in an 8-K filing that on October 23, 2026, its Board of Directors, acting on a recommendation from the Compensation Committee, raised the annual base salary of CEO Dr. Pardeep Nijhawan from $357,696 to $657,423, that of President Dr. Michael Brooks from $335,340 to $591,681, and that of CFO Peter Weiler from $300,000 to $525,938, under each executive's employment agreement, with the increases applied retroactively to July 1, 2026.1
The filing noted that the executives' base salaries had not been adjusted since 2023.1
The company also reiterated an existing arrangement for its CEO, stating that 90% of Dr. Nijhawan's monthly base salary that would otherwise be paid in cash will keep being delivered as fully vested restricted share units issued under the company's 2019 Equity Incentive Compensation Plan.1
Edesa said further detail on the compensation terms for Nijhawan, Brooks and Weiler is available in their employment agreements, which were filed as exhibits to the company's Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed on December 12, 2025.1
The 8-K was signed by Chief Financial Officer Peter J. Weiler and dated October 23, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.